Rate Benchmarking
Compare your rates with similar providers.
Select a published rate, define comparable providers, and see where that rate falls in your market.
See a sample rate comparisonHCPCS Q5117 (Kanjinti) Fee Schedule
Last Verified: October 2026
Healthcare providers use this code to document and receive reimbursement for visits that address moderate-level medical decision-making, often including multiple diagnoses or prescription management.
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
| Key Fact | Detail |
|---|---|
| Service Type | Temporary Codes Cancer, Vision and Other Associated Drugs |
| Complexity Level | Low |
| Medicaid Fee Schedule | View Medicaid rates for Q5117 |
| Medicare Payment Limit | $47.547  |
| WAC Price | Lorem ipsum dolor sit amet consectetur Lorem ipsum dolor sit amet consectetur VisitBuyandBill.com |
| Related NDC Codes | • 55513-0132-01 - KANJINTI (PF,LYOPHILIZED) 420 MG • 55513-0141-01 - KANJINTI (SDV,PF,LATEX-FREE) 150 MG |
National average reimbursement for HCPCS Q5117 by major payers:
$27.05
$29.92
$31.69
$27.13
Compare published rates across providers.
Choose a payer to see a sample of rates for HCPCS Q5117.
HCPCS Q5117
5 of 25 sample ratesHigher to lower in this preview
Chu Chen
Merrimack Valley Pediatric Associates, Inc.
$53.52Published rateBrittany Ptachick
Hroa 401k Plan
$25.80Published rateCrescent City Surgical Centre Operating Company, L.L.C.
Crescent City Surgical Centre
$20.50Published rateBradley Weisner
Urology Specialists Of The Carolinas, PLLC
$14.26Published rateChristopher Raio
Mercy Medical Center
$13.25Published rate
Get a free rate benchmark for your specialty.
Choose your state and specialty to build a report from payer-published rates.
Use market rates to prepare your payer proposal.
Payer Contract Negotiation
Draft a fee schedule renegotiation letter.
Use your fee schedule and market benchmarks to set target rates and draft a letter for your payer.
See a sample payer proposalHCPCS Q5117 vs. Other Cancer, Vision and Other Associated Drugs Codes
The HCPCS Q5117 code is part of the Temporary Codes services used for Cancer, Vision and Other Associated Drugs. It represents a moderate-complexity encounter and is one of several codes that vary based on time spent, level of medical decision-making, and documentation requirements.
The HCPCS Q5117 code involves more provider time and moderate medical decision-making, unlike lower-level codes that require less time and simpler assessments. It typically includes multiple diagnoses, medication management, or test interpretation, leading to higher reimbursement and more detailed documentation requirements.
| Code | Complexity | Description |
|---|---|---|
| 55513-0132-01-NDC | Moderate | KANJINTI (PF,LYOPHILIZED) 420 MG |
| 55513-0141-01-NDC | Moderate | KANJINTI (SDV,PF,LATEX-FREE) 150 MG |
| Q5116-HCPCS | Low | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg |
| Q5117-HCPCS | Low | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
What is a fee schedule?
A fee schedule is a list of fixed prices that healthcare providers charge for specific services, including HCPCS Q5117. These prices vary depending on payer type (Medicare, Medicaid, private insurance), geographic location, and provider contracts.
Understanding the Q5117 fee schedule helps patients estimate costs and providers optimize billing for accurate reimbursements.
Factors that affect fee schedules
Medicare & Medicaid Rates
Government-set reimbursement amounts
Private Insurance Rates
Negotiated rates between providers and insurance companies
Geographic Location
Costs may be higher in urban areas.
Provider Type
Hospital providers may have different rates than private practice.
FREE SAMPLE MARKET COMPARISON
Let's review your payer contracts side-by-side with the market.
Bring your top codes (like HCPCS Q5117) and we'll show you how you compare in 15 minutes or less.